







10th PAN-RUSSIAN GMP CONFERENCE

OVERVIEW OF GMP INSPECTION DEFICIENCIES


Directorate of Drugs, Narcotics, Psychotropics, and Precursors Production Control Indonesian FDA (BPOM RI)

Number of Conducted GMP Inspections










Number of Overseas Manufacturing Sites Inspected during 2022–2024




Data on GMP Inspections





Data on GMP Inspection Results by Facility



Number of GMP Certificates Refused and Revoked in 2022–2024

GMP Certification	2022	2023	2024
Number of GMP Certification Refused	2	0	4
Number of GMP Certification Revoked	6	0	1


Data on GMP Inspection Deficiencies





The classification of deficiencies is regulated under the Indonesian FDA Regulation Number 19 of 2025 concerning Amendment to the Indonesian FDA Regulation Number 9 of 2024 on Guidelines for Follow-Up Actions to the Surveillance Results of Medicines, Pharmaceutical Ingredients, Narcotics, Psychotropics, Precursors, and Addictive Substances, which refers to PIC/S PI 040-1 (2019) on PIC/S Guidance on Classification of GMP Deficiencies

Deficiency Number and Categories




Data on GMP Inspections






Categorization of GMP Inspection Deficiencies in 2022



Categorization of GMP Inspection Deficiencies in 2023 & 2024



Examples of Critical Deficiencies







Quality System

CAPA system ineffective, with repeated findings from the previous inspection not corrected.



Production

Production activities were not able to ensure the quality of sterile products and consistent compliance with established requirements.



Building and Facility

Inadequate design and maintenance of buildings, facilities, and equipment, posing a contamination risk and lacking consistent compliance with current regulatory requirements.



Quality Control

Quality control and analytical method validation were inadequate to ensure compliance with specifications and/or that testing was performed using appropriate methods.



Qualification, Validation, Calibration

Non-compliant calibration, qualification, and validation processes, with equipment still in use and production ongoing.



Contamination RIsk

Potential contamination/ crosscontamination and inadequate containment of penicillin and cephalosporins.





